NCT07172347

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Jiangsu vcare pharmaceutical technology co., LTD · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Conditions

• Non-segmental Vitiligo

Interventions

Type	Name	Description
DRUG	VC005 tablets	VC005 groups repeat administration for 52 weeks
DRUG	VC005 Tablets Placebo	VC005 Placebo groups repeat administration for 52 weeks

Timeline

• Start date: 2025-10-31
• Primary completion: 2027-08-30
• Completion: 2027-08-30
• First posted: 2025-09-15
• Last updated: 2026-01-02

Locations

1 site across 1 country: China